Literature DB >> 30368556

Differential capability of metabolic substrates to promote hepatocellular lipid accumulation.

Ngoc Anh Hoang1, Friederike Richter1, Martin Schubert2,3, Stefan Lorkowski2,3, Lars-Oliver Klotz1, Holger Steinbrenner4.   

Abstract

PURPOSE: Excessive storage of triacylglycerides (TAGs) in lipid droplets within hepatocytes is a hallmark of non-alcoholic fatty liver disease (NAFLD), one of the most widespread metabolic disorders in Western societies. For the purpose of exploring molecular pathways in NAFLD development and testing potential drug candidates, well-characterised experimental models of ectopic TAG storage in hepatocytes are needed.
METHODS: Using an optimised Oil Red O assay, immunoblotting and real-time qRT-PCR, we compared the capability of dietary monosaccharides and fatty acids to promote lipid accumulation in HepG2 human hepatoma cells.
RESULTS: Both high glucose and high fructose resulted in intracellular lipid accumulation after 48 h, and this was further augmented (up to twofold, as compared to basal levels) by co-treatment with the lipogenesis-stimulating hormone insulin and the pro-inflammatory cytokine tumour necrosis factor alpha (TNF-α), respectively. The fatty acids palmitic and oleic acid were even more effective than these carbohydrates, inducing significantly elevated TAG storage already after 24 h of treatment. Highest (about threefold) increases in lipid accumulation were observed upon treatment with oleic acid, alone as well as in combinations with palmitic acid or with high glucose and insulin. Increases in protein levels of a major lipid droplet coat protein, perilipin-2 (PLIN2), mirrored intracellular lipid accumulation following different treatment regimens.
CONCLUSIONS: Several treatment regimens of excessive fat and sugar supply promoted lipid accumulation in HepG2 cells, albeit with differences in the extent and rapidity of steatogenesis. PLIN2 is a candidate molecular marker of sustained lipid accumulation in HepG2 cells.

Entities:  

Keywords:  Adipophilin; DGAT2; Fatty liver; Glucosamine; Triglyceride

Mesh:

Substances:

Year:  2018        PMID: 30368556     DOI: 10.1007/s00394-018-1847-2

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  42 in total

Review 1.  Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Astrid Spruss; Ina Bergheim
Journal:  J Nutr Biochem       Date:  2009-09       Impact factor: 6.048

Review 2.  Non-alcoholic fatty liver disease: A sign of systemic disease.

Authors:  Isabella Reccia; Jayant Kumar; Cherif Akladios; Francesco Virdis; Madhava Pai; Nagy Habib; Duncan Spalding
Journal:  Metabolism       Date:  2017-04-27       Impact factor: 8.694

3.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

Review 4.  Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease.

Authors:  Christine C Hsu; Erik Ness; Kris V Kowdley
Journal:  Adv Nutr       Date:  2017-03-15       Impact factor: 8.701

Review 5.  Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.

Authors:  Samir Softic; David E Cohen; C Ronald Kahn
Journal:  Dig Dis Sci       Date:  2016-02-08       Impact factor: 3.199

6.  Epidemiology of non-alcoholic fatty liver disease.

Authors:  Stefano Bellentani; Federica Scaglioni; Mariano Marino; Giorgio Bedogni
Journal:  Dig Dis       Date:  2010-05-07       Impact factor: 2.404

Review 7.  Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Yoshihisa Takahashi; Yurie Soejima; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

8.  Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.

Authors:  Michael H Le; Pardha Devaki; Nghiem B Ha; Dae Won Jun; Helen S Te; Ramsey C Cheung; Mindie H Nguyen
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

Review 9.  Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease.

Authors:  Yuki Kawano; David E Cohen
Journal:  J Gastroenterol       Date:  2013-02-09       Impact factor: 7.527

Review 10.  In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD).

Authors:  Giridhar Kanuri; Ina Bergheim
Journal:  Int J Mol Sci       Date:  2013-06-05       Impact factor: 5.923

View more
  2 in total

1.  Dietary Polyphenols Protect Against Oleic Acid-Induced Steatosis in an in Vitro Model of NAFLD by Modulating Lipid Metabolism and Improving Mitochondrial Function.

Authors:  Hossein Rafiei; Kosar Omidian; Brian Bandy
Journal:  Nutrients       Date:  2019-03-03       Impact factor: 5.717

2.  Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis.

Authors:  Shaza Asif; Ri Youn Kim; Thet Fatica; Jordan Sim; Xiaoling Zhao; Yena Oh; Alix Denoncourt; Angela C Cheung; Michael Downey; Erin E Mulvihill; Kyoung-Han Kim
Journal:  Mol Metab       Date:  2022-04-12       Impact factor: 8.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.